GAIN OF CHROMOSOME 7 LOSS OF CHROMOSOME 10,TISSUE

What is Gain of Chromosome 7/Loss of Chromosome 10 Glioma, Tissue test?

Gain of Chromosome 7/Loss of Chromosome 10 (7+/10−) testing on glioma tissue detects broad copy‑number aneuploidies characteristic of IDH‑wildtype glioblastoma and related diffuse astrocytic tumors, supporting diagnosis, prognosis, and treatment planning in an integrated pathology report. This combined signature is among the most frequent genomic patterns in gliomas and often emerges early in tumor evolution, frequently accompanying other GBM‑type alterations such as EGFR pathway activation and TERT promoter mutation.

Why consider Gain of Chromosome 7/Loss of Chromosome 10 Glioma, Tissue test?

• Supports accurate classification and grading by identifying the canonical 7+/10− pattern linked to aggressive biology, thereby aiding distinction of IDH‑wildtype glioblastoma from other diffuse gliomas when histology is equivocal or limited.
• Provides prognostic information since co‑occurring 7 gain and 10 loss correlates with unfavorable outcomes compared with single‑arm changes, reflecting increased tumor fitness and therapy resistance in multiple datasets

Who should get tested for Gain of Chromosome 7/Loss of Chromosome 10 Glioma, Tissue test?

• Patients with newly diagnosed diffuse astrocytic tumors where IDH‑wildtype glioblastoma is suspected, especially when histology is borderline or biopsy is small and additional molecular criteria are required for definitive classification.
• Patients with recurrent/progressive tumors to reassess copy‑number evolution, complementing markers such as EGFR amplification, TERT promoter mutation, CDKN2A/B loss, and MGMT promoter methylation for comprehensive management decisions.

More Information about Gain of Chromosome 7/Loss of Chromosome 10 Glioma, Tissue test

OTHER NAMES: Chr7 gain/Chr10 loss signature; 7+/10− aneuploidy pattern; GBM‑type copy‑number signature; combined chromosome 7 polysomy with chromosome 10 monosomy (tissue).

Glioma is a primary tumor of glial cells in the brain and spinal cord, now classified primarily by molecular markers alongside histology, especially IDH mutation status and 1p/19q codeletion in adults. Modern classification separates adult diffuse gliomas into IDH‑mutant astrocytoma, IDH‑mutant and 1p/19q‑codeleted oligodendroglioma, and IDH‑wildtype glioblastoma, which differ in prognosis and therapy response.